Author

R. Majeti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2

Frequent Co-Authors

Y. Nakauchi· 2 shared A. Azizi· 1 shared A. Banuelos· 1 shared A. Barkal· 1 shared A. Delaidelli· 1 shared A. Deutzmann· 1 shared A. Ediriwickrema· 1 shared A. He· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Y. Nakauchi

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Convergent Epigenetic Evolution Drives Relapse in Acute Myeloid Leukemia

K. Nuno, A. Azizi, T. Koehnke, C. Lareau, A. Ediriwickrema, M. R. Corces, A. T. Satpathy, R. Majeti

This study identifies convergent epigenetic evolution in AML relapse using ATAC-seq and mtscATAC, showing that epigenetic changes drive relapse independent of genetic mutations.

bioRxiv · Oct 10, 2023Cancer Biology

AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML

E. C. Sayitoglu, B. A. Luca, A. P. Boss, B. C. Thomas, R. A. Freeborn, M. J. Uyeda, P. P. Chen, Y. Nakauchi, C. Waichler, N. J. Lacayo, R. Bacchetta, R. Majeti, A. J. Gentles, A.-M. Cepika, M. G. Roncarolo

The paper identifies ICAM1 as a key factor in T cell killing of AML by analyzing transcriptional programs in AML and T cell interactions.

bioRxiv · Sep 21, 2023Immunology

Genetically Corrected RAG2-SCID Human Hematopoietic Stem CellsRestore V(D)J-Recombinase and Rescue Lymphoid Deficiency

M. Pavel-Dinu, C. L. Gardner, Y. Nakauchi, T. Kawai, O. M. Delmonte, B. Palterer, M. Bosticardo, F. Pala, S. Viel, H. L. Malech, H. Y. Ghanim, N. N. Bode, G. L. Kurgan, C. A. Vakulskas, A. Sheikali, , M. H. Porteus

This study corrects the RAG2 gene in human hematopoietic stem cells to restore V(D)J recombination and lymphoid development in RAG2-SCID patients.

bioRxiv · Jul 12, 2022Immunology

Anti-GD2 antibody disrupts GD2:Siglec-7 interactions and synergizes with CD47 blockade to mediate tumor eradication

J. Theruvath, M. Menard, B. A. Smith, M. H. Linde, G. Coles, W. Wu, L. Kiru, A. Delaidelli, J. L. Silberstein, A. Banuelos, S. Dhingra, E. Sotillo, S. Heitzeneder, A. Tousley, J. Lattin, , R. G. Majzner

This study shows that combining anti-GD2 and anti-CD47 antibodies enhances anti-tumor responses by recruiting macrophages and disrupting the GD2:Siglec-7 interaction in GD2+ cancers.

bioRxiv · Mar 19, 2021 · PreprintImmunology

Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index

Y. Li, D. Thomas, A. Deutzmann, R. Majeti, D. Felsher, D. Dill

This study identifies mebendazole as a potential differentiation therapy for AML using a novel computational method called LMI, showing it induces differentiation and improves survival in mouse models.

bioRxiv · Jul 1, 2019Cancer Biology